We are live on ! Find out more
IBRX icon

ImmunityBio
IBRX

117 hedge funds and large institutions have $109M invested in ImmunityBio in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 24 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 24

22% more capital invested

Capital invested by funds: $89.2M → $109M (+$19.5M)

21% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $8.69M

1.63% less ownership

Funds ownership: 10.6% → 8.97% (-1.6%)

20% less funds holding

Funds holding: 146 → 117 (-29)

64% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 44

Holders
117
Holders Change
-29
Holders Change %
-19.86%
% of All Funds
1.84%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
50
Reduced
24
Closed
44
Calls
$10.5M
Puts
$8.69M
Net Calls
+$1.86M
Net Calls Change
+$1.8M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$7.16M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$5.79M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.22M
4
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$1.88M
5
Northern Trust
Northern Trust
Illinois
+$990K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$10.5M
2
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$6.79M
3
Cerity Partners
Cerity Partners
New York
-$5.07M
4
SSWM
Sheets Smith Wealth Management
North Carolina
-$3.74M
5
TCM
Tang Capital Management
California
-$1.99M
Name Holding Trade Value Shares
Change 		Change in
Stake
GRP
101
Global Retirement Partners
California
$2.58K – – –
AF
102
Advisornet Financial
Minnesota
$2.08K – – –
AAP
103
Arax Advisory Partners
Colorado
$1.67K – – –
QC
104
Quent Capital
New York
$1.22K +$99 +35 +9%
CTA
105
Colonial Trust Advisors
South Carolina
$1.18K – – –
SWM
106
Spire Wealth Management
Virginia
$1.17K – – –
SPIA
107
Steward Partners Investment Advisory
New York
$1.11K +$1.13K +400 New
BFEC
108
Benjamin F. Edwards & Company
Missouri
$1K – – –
CG
109
Cutler Group
California
$1K – – –
ATC
110
Adirondack Trust Company
New York
$990 – – –
PA
111
PSI Advisors
Florida
$973 – – –
Parallax Volatility Advisers
112
Parallax Volatility Advisers
California
$826 +$840 +297 New
NA
113
NewEdge Advisors
Louisiana
$695 – – –
BWM
114
BerganKDV Wealth Management
Minnesota
$320 – – –
CBT
115
Central Bank & Trust
Kentucky
$221 – – –
FGAM
116
Financial Gravity Asset Management
Texas
$26 +$8 +3 New
AC
117
Armistice Capital
New York
– -$10.5M -5,795,927 Closed
TCM
118
Tang Capital Management
California
– -$1.99M -1,095,795 Closed
Millennium Management
119
Millennium Management
New York
– -$948K -520,831 Closed
Squarepoint
120
Squarepoint
New York
– -$877K -481,915 Closed
OQS
121
Occudo Quantitative Strategies
Florida
– -$726K -399,046 Closed
Citadel Advisors
122
Citadel Advisors
Florida
– -$692K -244,721 Closed
Marshall Wace
123
Marshall Wace
United Kingdom
– -$427K -234,441 Closed
Tudor Investment Corp
124
Tudor Investment Corp
Connecticut
– -$358K -196,436 Closed
First Trust Advisors
125
First Trust Advisors
Illinois
– -$283K -155,497 Closed
3 4
5
6 7

IBRX Hedge Fund Activity: Q2 2023 in Review

117 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2023, worth a combined $109M — up 22% from $89.2M a quarter earlier.

Sellers outnumbered buyers: 44 funds closed out of IBRX and 16 opened new positions — a net loss of 28 holders — while 24 trimmed existing stakes and 50 added.

The largest buyer was BlackRock, adding an estimated $7.16M. The largest seller was Armistice Capital, exiting entirely with an estimated $10.5M sold.

  • 117 institutional investors held ImmunityBio (IBRX) as of Q2 2023, down from 146 in Q1 2023.
  • Funds reported $109M of ImmunityBio stock for Q2 2023, up 22% quarter-over-quarter.
  • 16 funds opened new ImmunityBio positions in Q2 2023 and 44 closed out, a net change of -28 holders.
  • The largest ImmunityBio buyer in Q2 2023 was BlackRock, an estimated $7.16M added.
  • The largest ImmunityBio seller in Q2 2023 was Armistice Capital, an estimated $10.5M sold.

Based on aggregated 13F filings for Q2 2023.